tirzepatide europe Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say NICE recommends Lilly's tirzepatide for

Current Perspectives on Long-Term Use Leading obesity medicine specialists and studies consistently suggest that for many, long-term or even lifelong treatment with medications like tirzepatide may be necessary to maintain weight loss and the associated health benefits

Tirzepatide belongs to a dual GIP and GLP-1 agonist class

How long tirzepatide stays in your system Understanding tirzepatide pharmacokinetics matters for blood work timing

3 Di AngelantonioEBhupathirajuSNWormserDGaoPKaptogeSDe GonzalezABet al

Of patients who underwent bariatric surgery, 76% lost at least 15% of their starting body weight within one year, as seen in Figure 2

In May 2022, tirzepatide received its first approval in the USA to improve glycaemic control in adults with T2DM, as an adjunct to diet and exercise